Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Dave, Vibhuti P ^a   Hajjar, Fadi ^a   Dieng, Mame Massar ^b   Haddad, Élie ^b,c   Cohen, Éric A ^a,c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

BST2; HIV 1 release; Humanized mice; Viral dissemination; Vpu

Indexed keywords

BST2 PROTEIN; CHEMOKINE RECEPTOR CCR5; HOST FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VPU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; E3 UBIQUITIN LIGASE RECRUITING DOMAIN; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOUSE; NONHUMAN; PROTEIN DOMAIN; VIREMIA; VIRUS LOAD; VIRUS RELEASE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; ANTIGENS, CD; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIREMIA; VIRUS RELEASE;

EID: 84887041456     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-128     Document Type: Article

References (50)

1. Blanco-Melo D, Venkatesh S, Bieniasz PD. Intrinsic cellular defenses against human immunodeficiency viruses. Immunity 2012, 37:399-411. 10.1016/j.immuni.2012.08.013, 22999946.
2. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012, 287:40875-40883. 10.1074/jbc.R112.416925, 23043100.
3. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 2006, 177:3260-3265.
4. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430. 10.1038/nature06553, 18200009.
5. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252. 10.1016/j.chom.2008.03.001, 2474773, 18342597.
6. Lehmann M, Rocha S, Mangeat B, Blanchet F, Uji IH, Hofkens J, Piguet V. Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog 2011, 7:e1002456. 10.1371/journal.ppat.1002456, 3240612, 22194693.
7. Venkatesh S, Bieniasz PD. Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog 2013, 9:e1003483. 10.1371/journal.ppat.1003483, 3715405, 23874200.
8. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin AG, Guatelli J, Schwartz O. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 2010, 6:e1000955. 10.1371/journal.ppat.1000955, 2887479, 20585562.
9. Jolly C, Booth NJ, Neil SJ. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 2010, 84:12185-12199. 10.1128/JVI.01447-10, 2976402, 20861257.
10. Barrett BS, Smith DS, Li SX, Guo K, Hasenkrug KJ, Santiago ML. A single nucleotide polymorphism in < italic > tetherin promotes retrovirus restriction < italic > in vivo. PLoS Pathog 2012, 8:e1002596. 10.1371/journal.ppat.1002596, 3310811, 22457621.
11. Liberatore RA, Bieniasz PD. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A 2011, 108:18097-18101. 10.1073/pnas.1113694108, 3207693, 22025715.
12. Vigan R, Neil SJ. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 2010, 84:12958-12970. 10.1128/JVI.01699-10, 3004320, 20926557.
13. McNatt MW, Zang T, Bieniasz PD. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog 2013, 9:e1003299. 10.1371/journal.ppat.1003299, 3635990, 23633949.
14. Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, Stephens EB, Opella SJ, Guatelli J. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 2012, 287:58-67. 10.1074/jbc.M111.296772, 3249111, 22072710.
15. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 2009, 5:e1000450. 10.1371/journal.ppat.1000450, 2679223, 19478868.
16. Dube M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 2010, 6:e1000856. 10.1371/journal.ppat.1000856, 2851737, 20386718.
17. Dube M, Paquay C, Roy BB, Bego MG, Mercier J, Cohen EA. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic 2011, 12:1714-1729. 10.1111/j.1600-0854.2011.01277.x, 21902775.
18. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2010, 7:51. 10.1186/1742-4690-7-51, 2890665, 20529266.
19. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998, 1:565-574. 10.1016/S1097-2765(00)80056-8, 9660940.
20. Tokarev AA, Munguia J, Guatelli JC. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol 2011, 85:51-63. 10.1128/JVI.01795-10, 3014196, 20980512.
21. Gustin JK, Douglas JL, Bai Y, Moses AV. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain. J Biol Chem 2012, 287:14837-14850. 10.1074/jbc.M112.349928, 3340234, 22383521.
22. Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P, Towers GJ, Neil SJ. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog 2010, 6:e1000843. 10.1371/journal.ppat.1000843, 2855335, 20419159.
23. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009, 83:7931-7947. 10.1128/JVI.00242-09, 2715753, 19515779.
24. Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT. beta-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology 2011, 8:9. 10.1186/1742-4690-8-9, 3049139, 21310048.
25. Kueck T, Neil SJ. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog 2012, 8:e1002609. 10.1371/journal.ppat.1002609, 3315493, 22479182.
26. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol 2010, 84:4089-4094. 10.1128/JVI.01549-09, 2849503, 20147395.
27. Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A, Specht A, Sauter D, Dobner T, Kirchhoff F. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 2010, 7:1. 10.1186/1742-4690-7-1, 2823648, 20078884.
28. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G, Cohen EA. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 2009, 83:4574-4590. 10.1128/JVI.01800-08, 2668474, 19244337.
29. Binette J, Dube M, Mercier J, Halawani D, Latterich M, Cohen EA. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology 2007, 4:75. 10.1186/1742-4690-4-75, 2170451, 17937819.
30. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992, 66:7193-7200. 240416, 1433512.
31. Magadan JG, Perez-Victoria FJ, Sougrat R, Ye Y, Strebel K, Bonifacino JS. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog 2010, 6:e1000869. 10.1371/journal.ppat.1000869, 2861688, 20442859.
32. Lama J, Mangasarian A, Trono D. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 1999, 9:622-631. 10.1016/S0960-9822(99)80284-X, 10375528.
33. Levesque K, Zhao YS, Cohen EA. Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem 2003, 278:28346-28353. 10.1074/jbc.M300327200, 12746459.
34. Wildum S, Schindler M, Munch J, Kirchhoff F. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 2006, 80:8047-8059. 10.1128/JVI.00252-06, 1563805, 16873261.
35. Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, Barker E. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 2010, 8:397-409. 10.1016/j.chom.2010.10.008, 3005698, 21075351.
36. Matusali G, Potesta M, Santoni A, Cerboni C, Doria M. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 2012, 86:4496-4504. 10.1128/JVI.05788-11, 3318642, 22301152.
37. Sato K, Misawa N, Fukuhara M, Iwami S, An DS, Ito M, Koyanagi Y. Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol 2012, 86:5000-5013. 10.1128/JVI.07062-11, 3347374, 22357275.
38. Chang JJ, Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2010, 202:S297-S301. 10.1086/655657, 2945608, 20846036.
39. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 2007, 81:1000-1012. 10.1128/JVI.01629-06, 1797449, 17079292.
40. Chen P, Hubner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007, 81:12582-12595. 10.1128/JVI.00381-07, 2169007, 17728240.
41. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, Uchil PD, Heidecker G, Mothes W. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One 2013, 8:e53138. 10.1371/journal.pone.0053138, 3538641, 23308151.
42. Coleman CM, Spearman P, Wu L. Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology 2011, 8:26. 10.1186/1742-4690-8-26, 3108291, 21504576.
43. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. Innate sensing of HIV-1 assembly by tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 2012, 12:633-644. 10.1016/j.chom.2012.10.007, 3556742, 23159053.
44. Lindwasser OW, Chaudhuri R, Bonifacino JS. Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency viruses. Curr Mol Med 2007, 7:171-184. 10.2174/156652407780059177, 17346169.
45. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF, Hermkes E, Moll M, Barker E, Peeters M, et al. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog 2012, 8:e1003093. 10.1371/journal.ppat.1003093, 3534379, 23308067.
46. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6:409-421. 10.1016/j.chom.2009.10.004, 2779047, 19917496.
47. Bego MG, Mercier J, Cohen EA. Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J Virol 2012, 86:3513-3527. 10.1128/JVI.06971-11, 3302510, 22301143.
48. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10:661-671. 10.1016/S1074-7613(00)80065-5, 10403641.
49. Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D, Cohen EA. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998, 187:1103-1111. 10.1084/jem.187.7.1103, 2212198, 9529326.
50. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 1990, 64:621-629. 249152, 2404139.